China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
Liver Cancer · 10.07.2025 · 1-57
DOI: 10.1159/000546574 ↗Kurz gefasst
Leitlinie in der Zeitschrift Liver Cancer, online erschienen am 10.07.2025. Verfasst von Jian Zhou und 59 weiteren Autor:innen. Beteiligte Einrichtung: Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 430 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC), which accounts for approximately 75–85% of primary liver cancers, ranks 4th in newly diagnosed cases among various types of cancer in China, and is the 2nd leading cause of cancer-related mortality, thereby posing a significant threat to the life and health of the Chinese population. Since the publication of the “Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China” in June 2017, which were updated by the China’s National Health Commission in December 2019 and December 2021, additional high-quality evidence from researchers worldwide regarding the diagnosis, staging, and treatment of HCC has emerged, necessitating another update to the guidelines. The new edition (2024 Edition) was written by more than 120 multidisciplinary experts in the field of HCC in China, which not only reflects the real-world situation in China but also may reshape the nationwide diagnosis and treatment of HCC. The new guideline aims to encourage the implementation of evidence-based practice and improve the national average 5-year survival rate for patients with HCC, as proposed in the “Healthy China 2030: A Vision for Health Care.”
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Pathology, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
- Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
- Department of Liver Surgery and Liver Transplantation, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
Zitieren
APA
Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Liu, L., Wen, T., Kuang, M., Zhang, B., Tao, K., Han, G., Yan, Z., Wang, M., Liu, R., Guo, J., Zeng, Z., Liang, P., Ren, Z., …, & Liu, H. (2025). China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). Liver Cancer, 1-57. https://doi.org/10.1159/000546574
Vancouver
Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al. China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition). Liver Cancer. 2025:1-57. doi:10.1159/000546574
BibTeX
@article{Zhou2025,
author = {Zhou, Jian and Sun, Huichuan and Wang, Zheng and Cong, Wenming and Zeng, Mengsu and Zhou, Weiping and Liu, Lianxin and Wen, Tianfu and Kuang, Ming and Zhang, Bixiang and Tao, Kaishan and Han, Guohong and Yan, Zhiping and Wang, Maoqiang and Liu, Ruibao and Guo, Jinhe and Zeng, Zhaochong and Liang, Ping and Ren, Zhenggang and Hou, Jinlin and Zhang, Yanqiao and Liu, Xiufeng and Pan, Hongming and Bi, Feng and Liang, Changhong and Chen, Min and Yan, Fuhua and Xu, Huixiong and Xie, Xiaoyan and Ju, Shenghong and Ji, Yuan and Yun, Jingping and Li, Zengshan and Bai, Xueli and Cai, Dingfang and Chen, Weixia and Chen, Yajin and Chen, Yongjun and Cheng, Wenwu and Cheng, Shuqun and Dai, Zhi and Dai, Chaoliu and Gao, Qiang and Guo, Rongping and Guo, Wengzhi and Guo, Yabing and Hua, Baojin and Huang, Xiaowu and Jiang, Hanyu and Jia, Weidong and Li, Qiu and Li, Tao and Li, Xiangcheng and Li, Xun and Li, Yaming and Li, Yexiong and Liang, Jun and Liang, Xiao and Ling, Changquan and Liu, Hui},
title = {China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)},
journal = {Liver Cancer},
year = {2025},
pages = {1--57},
doi = {10.1159/000546574}
}
EUVIMED